Delivery Order SPE2DB24D2105-SPE2DB25FAQFM
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Methylphenidate ER 36 mg tablets (100-count) with a ceiling value of $2,595.88 under a firm fixed-price contract. The award was made on September 15, 2025, with an ultimate completion date of September 16, 2025, and represents a competitively awarded, non-set-aside procurement. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for Methylphenidate ER 36 mg tablets (100-count units) with a ceiling value of $3,150.33. This is a firm fixed price delivery order with no set-aside designation, representing a competitive award under the federal pharmaceutical procurement process. The order is scheduled for completion by August 1, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Methylphenidate ER 36 mg tablets (100 count) under a firm fixed-price contract valued at $3,092.87. The award was made on July 30, 2025, with an ultimate completion date of July 31, 2025, with no set-aside designation applied. This delivery order represents a competitive award to the prime contractor, with performance to be executed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Methylphenidate ER 36 mg tablets (100 count) with a ceiling value of $2,501.99. This competitive, non-set-aside award was executed on September 11, 2025, with an ultimate completion date of September 12, 2025. The delivery order utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Methylphenidate ER 36 mg tablets (100-count units) with a ceiling value of $2,855.75. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award based on open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. The contract is scheduled...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Methylphenidate ER 36 mg tablets (100 count) on June 18, 2025, with a ceiling value of $1,738.16 and firm fixed pricing. This is a non-set-aside contract with an ultimate completion date of June 20, 2025, and performance will be conducted at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a pediatric attention deficit hyperactivity disorder medication...
- The Defense Logistics Agency awarded a delivery order valued at $1,073.04 to AmerisourceBergen Drug Corp for the supply of Methylphenidate ER 36 mg tablets (100-count units). This order, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a firm fixed-price, competitively awarded contract with no set-aside designation. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Methylphenidate ER 36 mg tablets (100-count bottles) valued at $1,461.07 on August 14, 2025, with completion expected by August 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. Methylphenidate is a Schedule II controlled substance commonly used to treat attention deficit...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Methylphenidate ER 36 mg tablets (100-count units) with a ceiling value of $9,456.85. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract's ultimate completion date is September 12, 2025, with performance to occur at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Methylphenidate ER 36 mg tablets (100 count) with a ceiling value of $1,995.16. The contract, awarded on June 9, 2025, with an ultimate completion date of June 10, 2025, was executed under firm fixed price terms with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAQFMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Methylphenidate ER 36 mg tablets (100-count) with a ceiling value of $1,222.60 under a firm fixed price arrangement. The contract was awarded on September 15, 2025, with an ultimate completion date of September 16, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The prime IDC serves as a comprehensive pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications and medical supplies to support military healthcare programs globally. Methylphenidate ER, a controlled-release formulation of a central nervous system stimulant commonly used to treat attention deficit hyperactivity disorder, represents part of the company's extensive pharmaceutical portfolio supporting Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/15/25 |